维拉帕米抑制P-糖蛋白可克服伴鼻息肉的慢性鼻窦炎中对莫米松的抵抗
本研究利用伴鼻息肉慢性鼻窦炎(CRSwNP)的离体鼻息肉外植体,探讨P-糖蛋白(P-gp)抑制是否增强莫米松的滞留与疗效。结果显示P-gp表达与莫米松组织滞留呈显著负相关,维拉帕米可逆转此抵抗并显著改善莫米松滞留,联合治疗还显著减少IL-5分泌且优于单药。
要点
- P-gp表达越高,莫米松组织滞留越少,提示P-gp参与糖皮质激素抵抗。
- 维拉帕米抑制P-gp可显著改善莫米松在鼻息肉组织中的滞留。
- 莫米松联合维拉帕米显著减少IL-5分泌,抗炎效果优于单药。
核心结论
- P-gp参与CRSwNP中对莫米松的抵抗,维拉帕米抑制P-gp可逆转该抵抗并增强莫米松的抗炎效果。
研究设计与样本
- IRB批准的离体研究,使用器官型鼻息肉外植体,分别暴露于莫米松(4.15 μg/mL)和维拉帕米(125 μg/mL)的单药及联合治疗。
主要发现
- P-gp表达与莫米松暴露后1小时的组织滞留呈强烈且显著的负相关,P-gp表达最低与最高的鼻息肉外植体间组织滞留相差近6倍。
- 维拉帕米抑制P-gp可逆转上述效应,在1小时时显著改善莫米松滞留(相对于单用莫米松)。
- 莫米松与维拉帕米联合显著减少IL-5分泌(相对于载体对照),且效果优于任一单药治疗。
临床怎么用
- 在CRSwNP中,P-gp表达可能作为糖皮质激素抵抗的潜在标志,联合P-gp抑制剂或可改善莫米松的局部滞留与抗炎疗效。
局限性
- 研究为离体鼻息肉外植体实验,样本量及在体临床适用性未在摘要中报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: P-glycoprotein (P-gp) is a membrane efflux pump which is overexpressed in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) and promotes Type 2 inflammation. Glucocorticoids (GC) are substrates of P-gp suggesting that overexpression may additionally contribute to GC resistance in CRSwNP. This study aims to determine whether P-gp inhibition using verapamil enhances mometasone retention and efficacy in nasal polyp explants. METHODOLOGY: IRB approved study in which organotypic polyp explants were exposed to mometasone (4.15 μg/mL) and verapa- mil (125 μg/mL) as mono and combination therapy. The effect of verapamil on mometasone tissue retention over time was deter- mined using HPLC. The effect of verapamil on mometasone anti-inflammatory function was determined using ELISA for secreted IL-5. Groups were compared using Kruskal-Wallis test. RESULTS: P-gp expression strongly and significantly inversely correlated with mometasone retention 1hr after exposure, with a ne- arly 6-fold reduction in tissue retention between the lowest and highest P-gp expressing polyp explants. P-gp inhibition reversed this effect and significantly improved mometasone retention at 1hr relative to mometasone alone. The combination of mome- tasone and verapamil significantly reduced IL-5 secretion relative to vehicle control and outperformed either treatment alone. CONCLUSIONS: Our study confirms that P-gp contributes to mometasone resistance. This P-gp mediated resistance was successfully reversed by addition of the P-gp inhibitor verapamil. Verapamil further significantly enhanced the anti-inflammatory effect of mometasone when given as a combination therapy.
引用
- Taha MS, Nocera A, Workman A, et al. P-glycoprotein inhibition with verapamil overcomes mometasone resistance in Chronic Sinusitis with Nasal Polyps. Rhinology. 2021. PMID: 33459729. doi:10.4193/Rhin20.551
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。